"Among other things, plaintiff alleges that prudent fiduciaries ... [1] continually supervise their PBM's actions to ensure that the plan is minimizing costs and maximizing outcomes for beneficiaries; [2] retain sufficient control over their plans' formularies to prevent the PBM from making formulary decisions that serve the PBM's interests but not the plan's interests; ... [3] will replace brand name drugs on the formulary when lower-cost, FDA-approved generics become available; and [4] are aware of the conflicts of interest that PBMs have in making formulary decisions." [Lewandowski v. Johnson & Johnson, No. 24-0671 (D.N.J. complaint filed Feb. 5, 2024)]  MORE >>